Lilly Reports Results of Lebrikizumab in P-III ADvocate 1 and 2 Studies for the Treatment of Moderate to Severe Atopic Dermatitis
Shots:
- The ongoing P-III ADvocate 1 & 2 studies evaluate lebrikizumab as monothx. vs PBO in adult & adolescent patients aged 12 to less than 18 yrs. with mod. to sev. AD for 52wks.
- The 1EPs & 2EPs of study i.e >75% change from baseline in EASI score @16wks.- improvement in skin clearance & itch including QoL while safety profile was consistent with prior studies of lebrikizumab
- Lilly gets exclusive rights for the development & commercialization of lebrikizumab in the US & other countries outside the EU while Almirall gets the rights to develop and commercialize the therapy for dermatology indications including the AD in the EU. The therapy has received FTD for a mod. to sev. AD
| Ref: PR Newswire | Image: Wall Street Journal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com